{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=17&state=Texas", "query": { "state": "Texas", "city": "Houston", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 22488, "total_pages": 2249, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=18&state=Texas&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=16&state=Texas&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T17:21:12.615Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01358266", "title": "Study Assessing Double-masked Uveitis Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveitis; Posterior, Disorder" ], "interventions": [ { "name": "DE-109 44 ug", "type": "DRUG" }, { "name": "DE-109 440 ug", "type": "DRUG" }, { "name": "DE-109 880 ug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 592, "start_date": "2011-05", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 71 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358266" }, { "nct_id": "NCT00030966", "title": "Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1200, "start_date": "2002-01", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2009-06-18", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030966" }, { "nct_id": "NCT01945866", "title": "Phase II Combination Steroid and Anti-VEGF for Persistent DME", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "intravitreal ranibizumab 0.3 mg", "type": "DRUG" }, { "name": "dexamethasone intravitreal implant", "type": "DRUG" }, { "name": "Sham injection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Jaeb Center for Health Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2014-02", "completion_date": "2017-06-05", "has_results": true, "last_update_posted_date": "2018-09-25", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 56, "location_summary": "Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Redlands", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01945866" }, { "nct_id": "NCT03611075", "title": "A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autism Spectrum Disorder" ], "interventions": [ { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "5 Years to 45 Years" }, "enrollment_count": 144, "start_date": "2018-08-13", "completion_date": "2020-05-21", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 15, "location_summary": "Dothan, Alabama • Phoenix, Arizona • San Diego, California + 12 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03611075" }, { "nct_id": "NCT04308512", "title": "Care Coordination System for People With Dementia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Dementia", "Dementia Alzheimers" ], "interventions": [ { "name": "Active Nili device", "type": "BEHAVIORAL" }, { "name": "Passive Nili system", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Bijan Najafi, PhD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2021-12-01", "completion_date": "2025-08-01", "has_results": true, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04308512" }, { "nct_id": "NCT05176665", "title": "EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Neoplasm Metastasis", "Metastatic Gastrointestinal Carcinoid Tumor" ], "interventions": [ { "name": "EMB-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2021-10-21", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-08-26", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176665" }, { "nct_id": "NCT07222267", "title": "An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-75202", "type": "DRUG" }, { "name": "CDK4 Inhibitor", "type": "DRUG" }, { "name": "Estrogen Receptor Antagonist", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2025-12-11", "completion_date": "2037-01-13", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 6, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222267" }, { "nct_id": "NCT03565900", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 277, "start_date": "2018-09-12", "completion_date": "2021-11-04", "has_results": true, "last_update_posted_date": "2023-07-28", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 13, "location_summary": "Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565900" }, { "nct_id": "NCT01000311", "title": "A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meningococcal Disease" ], "interventions": [ { "name": "MenACWY-CRM", "type": "BIOLOGICAL" }, { "name": "DTaP-IPV/Hib", "type": "BIOLOGICAL" }, { "name": "HBV", "type": "BIOLOGICAL" }, { "name": "PCV", "type": "BIOLOGICAL" }, { "name": "MMR", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Days", "maximum_age": "89 Days", "sex": "ALL", "summary": "55 Days to 89 Days" }, "enrollment_count": 529, "start_date": "2009-11", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Canoga Park", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000311" }, { "nct_id": "NCT01625234", "title": "Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Phase I: X-396 (ensartinib)", "type": "DRUG" }, { "name": "Phase II: X-396 (ensartinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xcovery Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2012-06", "completion_date": "2020-09-17", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-11-03T17:21:12.615Z", "location_count": 14, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625234" } ] }